Histone H3K27M is a driving mutation in diffuse intrinsic pontine glioma (DIPG), a deadly pediatric brain tumor. The malignant and treatment-resistant brain tumor is a target for anti-cancer studies using cell penetrating peptides.<\/p>\n\n\n\n
Through a global inhibition of PRC2 catalytic activity and displacement of H3K27me2\/3, H3K27M reshapes the epigenome and promotes oncogenesis of DIPG. Consequentially, the histone modification H3K36me2, antagonistic to H3K27me2\/3, is elevated. The relationship and role of H3K36me2 in H3K27M-DIPG was investigated by approaches to its upstream catalyzing enzymes, NSD1 and NSD2, the \u201cwriters\u201d, and its downstream binding factors, LEDGF and HDGF2, the \u201creaders\u201d.<\/p>\n\n\n\n
Tumor-promoting transcriptional programs in H3K27M-DIPG were found to be disrupted by loss of NSD1 and NSD2, thus impeding cellular proliferation and tumorigenesis.
Downstream, a chemically modified peptide mimicking endogenous H3K36me2 was found to dislodge LEDGF and HDGF2 from chromatin. As LEDGF and HDGF2 are the main readers mediating the protumorigenic effects downstream of NSD1\/2-H3K36me2, dislodging them resulted in inhibition of H3K27M-DIPG proliferation.<\/p>\n\n\n\n
Histone H3K27M is a driving mutation in diffuse intrinsic pontine glioma (DIPG), a deadly pediatric brain tumor. The malignant and treatment-resistant brain tumor is a target for anti-cancer studies using cell penetrating peptides. Through a global inhibition of PRC2 catalytic … Continue reading
In this study, the chemically modified peptides used were cell penetrating peptides purchased from LifeTein.<\/a>
Reference: Sci. Adv. 2021 Jul 14; 7(29)
<\/p>\n","protected":false},"excerpt":{"rendered":"